We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

119 hedge funds and large institutions have $593M invested in Akebia Therapeutics in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 16 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

891% more call options, than puts

Call options by funds: $2.2M | Put options by funds: $222K

250% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 16

51% more capital invested

Capital invested by funds: $392M → $593M (+$202M)

9% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 22

1% more funds holding

Funds holding: 118 → 119 (+1)

0.19% less ownership

Funds ownership: 64.17% → 63.98% (-0.19%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
119
Holders Change
+1
Holders Change %
+0.85%
% of All Funds
2.97%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
24
Increased
56
Reduced
16
Closed
22
Calls
$2.2M
Puts
$222K
Net Calls
+$1.98M
Net Calls Change
+$848K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$15.5M
2
PA
Perceptive Advisors
New York
+$8.15M
3
Invesco
Invesco
Georgia
+$7.19M
4
Norges Bank
Norges Bank
Norway
+$6.09M
5
Renaissance Technologies
Renaissance Technologies
New York
+$6.08M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$12M
2
NCM
Nantahala Capital Management
Connecticut
-$12M
3
EAM
Eagle Asset Management
Florida
-$7.41M
4
CLCM
Crawford Lake Capital Management
New Jersey
-$4.65M
5
First Manhattan
First Manhattan
New York
-$4.24M
Name Holding Trade Value Shares
Change 		Change in
Stake
CM
126
Crestline Management
Texas
– -$504K -35,098 Closed
Voloridge Investment Management
127
Voloridge Investment Management
Florida
– -$490K -34,090 Closed
Jane Street
128
Jane Street
New York
– -$376K -26,186 Closed
BCM
129
BlueMar Capital Management
Florida
– -$356K -24,800 Closed
HCM
130
Highbridge Capital Management
New York
– -$352K -24,522 Closed
ARTA
131
A.R.T. Advisors
New York
– -$327K -22,770 Closed
Citadel Advisors
132
Citadel Advisors
Florida
– -$315K -20,470 Closed
FRM
133
Fox Run Management
Connecticut
– -$270K -18,800 Closed
Tudor Investment Corp
134
Tudor Investment Corp
Connecticut
– -$175K -12,155 Closed
CSS
135
Cubist Systematic Strategies
Connecticut
– -$159K -11,038 Closed
GC
136
Guggenheim Capital
Illinois
– -$157K -10,921 Closed
DCM
137
Driehaus Capital Management
Illinois
– -$148K -10,313 Closed
PHK
138
Point72 Hong Kong
Hong Kong
– -$55K -3,828 Closed
DADC
139
D.A. Davidson & Co
Montana
– -$6K -480 Closed
MAM
140
Meeder Asset Management
Ohio
– -$5K -317 Closed
FO
141
FT Options
Illinois
– -$461 -30 Closed
2 3 4 5
6

AKBA Hedge Fund Activity: Q3 2017 in Review

119 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2017, worth a combined $593M — up 51% from $392M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new AKBA positions and 22 closed out — a net gain of 2 holders — while 56 added to existing stakes and 16 trimmed.

The largest buyer was BlackRock, adding an estimated $15.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $12M sold.

  • 119 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2017, up from 118 in Q2 2017.
  • Funds reported $593M of Akebia Therapeutics stock for Q3 2017, up 51% quarter-over-quarter.
  • 24 funds opened new Akebia Therapeutics positions in Q3 2017 and 22 closed out, a net change of +2 holders.
  • The largest Akebia Therapeutics buyer in Q3 2017 was BlackRock, an estimated $15.5M added.
  • The largest Akebia Therapeutics seller in Q3 2017 was RA Capital Management, an estimated $12M sold.

Based on aggregated 13F filings for Q3 2017.